REPL Stock Risk & Deep Value Analysis
Replimune Group Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About REPL Stock
We analyzed Replimune Group Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran REPL through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is REPL Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
High
What Are the Red Flags for REPL?
- ⚠
Negative or inconclusive pivotal RP1 data readout (Q2 2026)
- ⚠
Regulatory delays or rejection of BLA filing
- ⚠
Need for additional dilutive financing if RP1 data is not strong enough for partnership advances
- ⚠
Competitive product advancements
Unlock REPL Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Replimune Group Inc (REPL) Do?
Market Cap
$698.21M
Sector
Healthcare
Industry
Biotechnology
Employees
479
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Visit Replimune Group Inc WebsiteIs REPL Stock Undervalued?
Unlock the full AI analysis for REPL
Get the complete DVR score, risk analysis, and more
Does REPL Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The moat is primarily built on the uniqueness and clinical efficacy of its IMMPACT platform and the robust IP protecting RP1. Successful clinical trials and subsequent regulatory approvals will significantly strengthen this moat by establishing a new standard of care.
Moat Erosion Risks
- •Failure of RP1 in pivotal trials, undermining the entire platform's credibility
- •Emergence of superior competitive therapies with better efficacy or safety profiles
- •Loss or expiration of key intellectual property rights
REPL Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive REPL Stock Higher?
Near-Term (0-6 months)
- •Pivotal Phase 2 data for RP1 in advanced melanoma and CSCC (Q2 2026)
- •Q1 2026 Earnings Report (Estimated early May 2026)
- •Updates on RP2 and RP3 pipeline progression
Medium-Term (6-18 months)
- •Potential Biologics License Application (BLA) filing for RP1 (late 2026/early 2027)
- •Further expansion or updates to Bristol Myers Squibb collaboration
- •Initiation of additional Phase 3 trials for RP1 in new indications
Long-Term (18+ months)
- •Commercialization and market penetration of RP1
- •Validation of the IMMPACT oncolytic immunotherapy platform across multiple indications
- •Potential acquisition target by a large pharmaceutical company
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for REPL?
- ✓
Positive pivotal RP1 data readout in Q2 2026 (PRIMARY SIGNAL)
- ✓
Updates on regulatory interactions and BLA filing timelines
- ✓
Burn rate and cash runway for future operations
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for REPL (Replimune Group Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
